Accent Therapeutics has dosed the first subject in an open-label Phase I/II trial of ATX-295, an oral kinesin family member ...

More than just a tool for advancing pipelines, trial efficiency is the name of the game when it comes to synthetic control ...

BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...

Corxel Pharmaceuticals has received investigational new drug (IND) application clearance from the US FDA for the trial of CX11 for obesity.